Profil
Cindy Wong served as an Independent Director at Hansa Biopharma AB from 2012 to 2016.
She was also the Chief Medical Officer & Head-Medical Affairs at Q-Med AB and Vice President & Head-Global Clinical Development at Merz Pharmaceuticals GmbH.
Currently, she is the Chief Medical Officer at Moberg Pharma AB and the Chief Marketing Officer at OncoZenge AB.
Dr. Wong holds a doctorate degree from the University of Adelaide.
Anciens postes connus de Cindy Wong
| Sociétés | Poste | Fin |
|---|---|---|
| MOBERG PHARMA AB | Chief Tech/Sci/R&D Officer | 01/01/2023 |
| HANSA BIOPHARMA AB | Director/Board Member | 11/05/2016 |
Merz Pharmaceuticals GmbH
 Merz Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Merz Pharmaceuticals GmbH discovers and develops drugs for the treatment of neurological and psychiatric diseases. Its dermatology products focus on the treatment of scars, acne, hair loss and fungal diseases. In the area of metabolic disturbances, it offers therapies for liver disease and lipid metabolism disorders. The company also offers various OTC products, including cold remedies, skin care products and vitamin supplements under the brand names tetesept and Merz Special. The company is headquartered in Frankfurt am Main, Germany. | Corporate Officer/Principal | - |
| ONCOZENGE AB | Sales & Marketing | - |
Q-Med AB
 Q-Med AB Medical SpecialtiesHealth Technology Q-Med AB specializes in aesthetic and corrective solutions. It develops and manufactures brand management for aesthetic and corrective treatments, whereas its portfolio is based on the company’s patented technology, NASHA, for the production of stabilise of non-animal hyaluronic acid. The firm offers portfolio including the brands Restylane, Emervel, Azzalure, Dysport, Deflux, Solesta, and Durolane are other products improving patients’ health in the corrective field. The company was founded by Bengt Agerup on June 17, 1985 and is headquartered in Uppsala, Sweden. | Chief Tech/Sci/R&D Officer | - |
Formation de Cindy Wong
| University of Adelaide | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MOBERG PHARMA AB | Health Technology |
| HANSA BIOPHARMA AB | Health Technology |
| ONCOZENGE AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
Q-Med AB
Q-Med AB Medical SpecialtiesHealth Technology Q-Med AB specializes in aesthetic and corrective solutions. It develops and manufactures brand management for aesthetic and corrective treatments, whereas its portfolio is based on the company’s patented technology, NASHA, for the production of stabilise of non-animal hyaluronic acid. The firm offers portfolio including the brands Restylane, Emervel, Azzalure, Dysport, Deflux, Solesta, and Durolane are other products improving patients’ health in the corrective field. The company was founded by Bengt Agerup on June 17, 1985 and is headquartered in Uppsala, Sweden. | Health Technology |
Merz Pharmaceuticals GmbH
Merz Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Merz Pharmaceuticals GmbH discovers and develops drugs for the treatment of neurological and psychiatric diseases. Its dermatology products focus on the treatment of scars, acne, hair loss and fungal diseases. In the area of metabolic disturbances, it offers therapies for liver disease and lipid metabolism disorders. The company also offers various OTC products, including cold remedies, skin care products and vitamin supplements under the brand names tetesept and Merz Special. The company is headquartered in Frankfurt am Main, Germany. | Health Technology |
